Volume 8 Supplement 1

The Framingham Heart Study 100,000 single nucleotide polymorphisms resource

Open Access

Genome-wide association with select biomarker traits in the Framingham Heart Study

  • Emelia J Benjamin1, 2, 3, 4Email author,
  • Josée Dupuis1, 4,
  • Martin G Larson1, 5,
  • Kathryn L Lunetta1, 4,
  • Sarah L Booth6,
  • Diddahally R Govindaraju1, 2,
  • Sekar Kathiresan7, 8,
  • John F KeaneyJr2, 3,
  • Michelle J Keyes1, 5,
  • Jing-Ping Lin10,
  • James B Meigs9,
  • Sander J Robins1, 2,
  • Jian Rong1, 4,
  • Renate Schnabel1, 2,
  • Joseph A Vita2, 3,
  • Thomas J Wang8,
  • Peter WF Wilson11,
  • Philip A Wolf1, 2 and
  • Ramachandran S Vasan1, 2, 3
BMC Medical Genetics20078(Suppl 1):S11

DOI: 10.1186/1471-2350-8-S1-S11

Published: 19 September 2007

Abstract

Background

Systemic biomarkers provide insights into disease pathogenesis, diagnosis, and risk stratification. Many systemic biomarker concentrations are heritable phenotypes. Genome-wide association studies (GWAS) provide mechanisms to investigate the genetic contributions to biomarker variability unconstrained by current knowledge of physiological relations.

Methods

We examined the association of Affymetrix 100K GeneChip single nucleotide polymorphisms (SNPs) to 22 systemic biomarker concentrations in 4 biological domains: inflammation/oxidative stress; natriuretic peptides; liver function; and vitamins. Related members of the Framingham Offspring cohort (n = 1012; mean age 59 ± 10 years, 51% women) had both phenotype and genotype data (minimum-maximum per phenotype n = 507–1008). We used Generalized Estimating Equations (GEE), Family Based Association Tests (FBAT) and variance components linkage to relate SNPs to multivariable-adjusted biomarker residuals. Autosomal SNPs (n = 70,987) meeting the following criteria were studied: minor allele frequency ≥ 10%, call rate ≥ 80% and Hardy-Weinberg equilibrium p ≥ 0.001.

Results

With GEE, 58 SNPs had p < 10-6: the top SNPs were rs2494250 (p = 1.00*10-14) and rs4128725 (p = 3.68*10-12) for monocyte chemoattractant protein-1 (MCP1), and rs2794520 (p = 2.83*10-8) and rs2808629 (p = 3.19*10-8) for C-reactive protein (CRP) averaged from 3 examinations (over about 20 years). With FBAT, 11 SNPs had p < 10-6: the top SNPs were the same for MCP1 (rs4128725, p = 3.28*10-8, and rs2494250, p = 3.55*10-8), and also included B-type natriuretic peptide (rs437021, p = 1.01*10-6) and Vitamin K percent undercarboxylated osteocalcin (rs2052028, p = 1.07*10-6). The peak LOD (logarithm of the odds) scores were for MCP1 (4.38, chromosome 1) and CRP (3.28, chromosome 1; previously described) concentrations; of note the 1.5 support interval included the MCP1 and CRP SNPs reported above (GEE model). Previous candidate SNP associations with circulating CRP concentrations were replicated at p < 0.05; the SNPs rs2794520 and rs2808629 are in linkage disequilibrium with previously reported SNPs. GEE, FBAT and linkage results are posted at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007.

Conclusion

The Framingham GWAS represents a resource to describe potentially novel genetic influences on systemic biomarker variability. The newly described associations will need to be replicated in other studies.

Background

There is intense clinical and research interest in blood and urinary biomarkers to diagnose disease, to risk stratify individuals for prognosis and potential intervention, and to provide insights into disease pathogenesis [1]. Hence, it has been proposed that biomarkers may prove useful in the goal of developing what has been referred to as "predictive, preemptive, personalized medicine" [2].

In the present analysis, we examined biomarkers involving four biological systems: inflammation, natriuretic peptides, hepatic function, and vitamins. Circulating inflammatory, natriuretic peptides [35], hepatic function [6, 7] and vitamin [8] biomarker concentrations have been linked to increased risk of cardiovascular disease and mortality. For instance, the inflammatory marker C-reactive protein (CRP) predicts incident stroke [9], coronary heart disease [1012], and all-cause mortality [13].

Because of their prognostic importance, there has been interest in understanding the environmental and genetic factors contributing to interindividual variability in systemic biomarker concentrations. Prior reports support the heritability of systemic biomarker concentrations reflecting inflammatory processes [14, 15], natriuretic peptides activation [16], hepatic function [17, 18], and vitamin metabolism [19]. The majority of prior studies examining the genetic contribution to biomarker concentrations have examined genetic linkage or variation in selected candidate genes. Although there have been some successes with both approaches [20], the specific genes contributing to variability of most circulating biomarkers are incompletely understood. We examined the relation of single nucleotide polymorphisms (SNPs) on the Affymetrix 100K chip to variation in systemic biomarker concentrations. The GWAS approach has the advantage that it is not constrained by known physiologic associations.

Materials and methods

Study sample

The biomarkers were assessed in the Framingham Offspring sample, which is described in the Framingham 100K Overview [21]. Briefly, the Framingham Offspring were recruited in 1971–1974 from the children (and children's spouses) of the Framingham Original Cohort [22]. The examinations and the number of participants in which the biomarkers were assessed vary by analyte, as noted in Table 1.
Table 1

Types of traits phenotype master trait table, exam cycle, numbers of participants in family plates with phenotype

Phenotype

Acronym

Trait N = 27*

Subject N

Offspring Exam

Adjustment* Multivariable model

Inflammation/Oxidative Stress

CD40 Ligand, serum & plasma

CD40L

2

998

7

Age, sex, smoking, systolic and diastolic blood pressure, hypertension treatment, body mass index, waist circumference, Total/HDL cholesterol, triglyceride, lipid lowering medication, glucose, diabetes, aspirin, hormone replacement therapy and prevalent cardiovascular disease

C-reactive protein

CRP

5

980–1008

2, 5, 6, 7; Average: 2, 6, 7

 

Intercellular adhesion molecule-1

ICAM1

1

1006

7

 

Interleukin-6

IL6

1

1006

  

Urinary isoprostanes/creatinine

IsoCrUrine

1

828

  

Monocyte chemoattractant protein-1

MCP1

1

989

  

Myeloperoxidase

MPO

1

974

  

Osteoprotegerin

OPG

1

1005

  

P-selectin

Pselectin

1

1007

  

Tumor necrosis factor alpha

TNFA

1

753

  

Tumor necrosis factor receptor-2

TNFRII

1

980

  

Natriuretic Peptides

N-terminal pro-atrial natriuretic peptide

ANP

1

938

6

Age, sex, BMI, SBP, HTN Rx, LDL Total/HDL, diabetes, LV mass, LA size, CVD

B-type natriuretic peptide

BNP

1

938

  

Liver Function

Bilirubin

Bili

1

910

2

Age, sex, BMI, HDL, HTN, diabetes, serum total protein, alcohol intake, TG, & smoking

Aspartate aminotransferase **

AST

1

904

  

Alanine aminotransferase

ALT

1

904

  

Alkaline phosphatase

AlkPhos

1

904

  

Gamma-glutamyl transferase

GGT

1

896

  

Vitamins

Vitamin K plasma phylloquinone

VitKPhylloq

1

518

6/7

Age, sex, SBP, DBP, BMI, waist, total/HDL, smoking, glucose, TG, diabetes, HTN Rx, lipid lowering Rx, hormone replacement Rx, asthma Rx, alcohol use, prevalent CVD

Vitamin K percentage of undercarboxylated osteocalcin

VitKPucOC

1

504

  

Vitamin D plasma 25(OH)-D

VitD25OH

1

517

  

*Each trait had 2 adjustment schemes web posted: age- and sex-adjusted, and multivariable-adjusted at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007. GEE and FBAT traits are web displayed pha001115 through pha001218; Linkage traits are located from pha002301 through pha002352. In the present manuscript we examine the multivariable-adjusted trait, which we count as 1 trait. Note: biomarkers were natural log transformed due to skewed distribution; **normalized deviates. Vitamin measurements straddled exams 6 & 7, covariates from same exam biomarker assayed. SBP, DBP = systolic and diastolic blood pressure, HTN Rx = hypertension treatment, BMI = body mass index, TC/HDL = total/high density lipoprotein cholesterol; TG = triglyceride, HRT = hormone replacement therapy, Rx = medication therapy, CVD = cardiovascular disease; LDL = low density lipoprotein; LV mass = left ventricular mass; LA size = left atrial size; Atrial natriuretic peptide = N-terminal pro-atrial natriuretic peptide.

Phenotype definitions and methods

Biomarkers were measured on morning specimens after an overnight fast (typically 10 hours) between 7:30 and 9:00 am. EDTA and citrated blood collection tubes are centrifuged in a refrigerated centrifuge immediately after venipuncture. Serum blood collection tubes sit for 30 minutes after venipuncture to allow for complete clotting. Specimens are processed immediately after centrifugation. Blood samples were centrifuged and frozen at -20° (examination 2 through 4) and -80° (examinations 5 through 7). The measurement of the inflammatory markers is detailed in the inflammatory marker manual at the National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007.

Inflammatory biomarkers (except CRP) were measured in duplicate with commercially available ELISA kits: R&D Systems (intercellular adhesion molecule-1, interleukin-6, monocyte chemoattractant-1 [MCP1], P-selectin, tumor necrosis factor receptor 2, high sensitivity tumor necrosis factor-α), Bender MedSystems (CD40 ligand), Oxis (myeloperoxidase), and BIOMEDICA (osteoprotegerin). High-sensitivity CRP was measured in 2002 and 2004 on examination cycle 2, 6 and 7 specimens with a Dade Behring nephelometer; the less sensitive Hemagen assay was used in 1998 for examination cycle 5 specimens. Natriuretic peptides were measured by Shionogi using a noncompetitive high sensitivity immunoradiometric assay [23]. Liver function tests were measured at examination cycle 2 by Quest Diagnostics (previously METPATH) with a variety of methods: γ-glutamyl aminotransferase was measured with spectrophotometry [7], bilirubin was measured by the colorimetric method (Dow Bilirubin Kit) [24, 25]; alkaline phosphatase was measured with the kinetic method [26, 27]; aspartate aminotransferase and alanine aminotransferase were measured using the kinetic method with Beckman Liquid-Stat Reagent Kit [28]. Vitamin K status was measured as phylloquinone concentrations with reverse phase high-performance liquid chromatography [29], and percentage of undercarboxylated osteocalcin was measured by radioimmunoassay [30, 31], Vitamin D status was measured as 25(OH)D concentrations by using RIA (DiaSorin, Stillwater MN).

Plasma samples were used for natriuretic peptides, vitamin K phylloquinone, vitamin D, and some inflammatory markers including CD40 ligand, osteoprotegerin, P-selectin, tumor necrosis factor receptor 2, and tumor necrosis factor-α. Serum samples were analyzed for liver function, vitamin K, % undercarboxylated osteocalcin, and other inflammatory markers including CRP, interleukin-6, soluble intracellular adhesion molecule-1, MCP1, and myeloperoxidase concentrations. The reproducibility of the biomarkers was good; the intra-assay coefficients of variation were CD40 ligand 4.4%, interleukin-6 3.1%, intercellular adhesion molecule-1 3.1%, MCP1 4.1%, myeloperoxidase 3.0%, osteoprotegerin 3.7%, P-selectin 3.0%, tumor necrosis factor-α 8.8%, and tumor necrosis factor receptor-2 2.3%; the inter-assay coefficients of variation were brain natriuretic peptide 12.2%, n-terminal-atrial natriuretic peptide 12.7%. The Kappa statistic for 146 CRP samples run in duplicate was 0.95 [32]. Coefficients of variation for aspartate aminotransferase and alanine aminotransferase, respectively, were 10.7 and 8.3%. The coefficients of variation for low and high Vitamin K plasma phylloquinone concentrations were 15.2 and 10.9% respectively on control specimens. For low, medium and high osteocalcin concentrations used to determine Vitamin K percentage of undercarboxylated osteocalcin, the coefficients of variation were 22.3, 12.8, and 7.8%, respectively. For Vitamin D, the coefficients of variation were 8.5% and 13.2%, respectively.

Genotyping methods

Details of the genotyping methods are available in the Framingham Heart Study 100K Overview [21]. Framingham staff extracted genomic DNA with a Qiagen Blood and Cell Culture Maxi Kit from immortalized lymphoblasts. Briefly, SNPs on the Affymetrix 100K chip were genotyped (n = 112,990 autosomal SNPs) in a sample of family members of the Original and Offspring cohorts of the Framingham Heart Study [33]. SNPs were excluded for the following reasons: minor allele frequency <10% n = 38062; call rate <80% n = 2346; Hardy-Weinberg equilibrium p-value < 0.001 n = 1595, leaving 70,987 SNPs available for analysis.

Statistical analysis methods

We created standardized multivariable-adjusted natural log transformed biomarker residuals adjusted for the covariates listed in Table 1. The CRP average residuals were constructed as follows: (1) create age- and sex-adjusted or multivariable-adjusted residual at each of exams 2, 6 and 7; (2) take average of the residuals across exams; (3) the residual was excluded if there were not at least 2 exams for its calculation. In some instances we performed additional transformation (e.g. Winsorized models). Tobit models were used to generate residuals for the natriuretic peptides, because 2% of N-ANP levels and 30% of BNP levels were below the respective assay detection limits. Association and linkage results examining age- and sex-adjusted residuals are posted at the web site. As described in the Overview [21], we examined generalized estimating equations (GEE) and family based association testing (FBAT), assuming an additive genetic effect, to account for correlation among related individuals within nuclear families. We also used Merlin software [34] (splitting the largest families) to compute exact identity by descent linkage, with variance component analysis in SOLAR using 11,200 SNPs and short tandem repeats [35]. Traits with extreme values, as defined by 4 standard deviations away from the mean, were Winsorized at 4.0 in secondary linkage analyses to determine the sensitivity of the logarithm of the odds (LOD) score to the presence of outlier values.

Results

Twenty-two biomarker traits (plus 4 additional CRP traits) were analyzed in 1012 Offspring participants, on log-transformed multivariable-adjusted residuals as outlined in Table 1 (minimum-maximum per phenotype n = 507–1008). The phenotypes were collected at various Framingham Offspring examinations from cycles 2 to 7. At examination cycles 2 and 7 the mean age of the participants with both phenotype and genotype data was 41 ± 10 and 59 ± 10 years, and 51.2% and 51.1% were women, respectively. For details of biomarker phenotype-genotype association refer to http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007.

There were 58 SNPs associated with biomarker concentrations with a p < 10-6 by GEE. The 25 most statistically significant GEE associations sorted by p-value, listed with their corresponding FBAT p-value are shown in Table 2a. MCP1 concentrations were associated with rs2494250 (p = 1*10-14) and rs4128725 (p = 3.68*10-12), both on chromosome 1, near the FCER1A and the OR10J1 genes, respectively. CRP concentrations averaged over 3 examinations (about 20 years) were associated with rs2794520 (p = 2.83*10-8) and rs2808629 (p = 3.19*10-8).
Table 2

Top genetic associations with biomarkers based on the lowest p value for GEE test (2a), FBAT (2b), and Linkage (2c)

2a. Top 25 associations with biomarkers based on the lowest p value of the GEE test

Trait

SNP rs ID*

Chr

Physical location (bp)

GEE P-value

FBAT P-value

IN/NEAR gene

 

Monocyte chemoattractant protein-1

rs2494250

1

156091324

1.0*10 -14

3.5*10-8

FCER1A, OR10J3

 

Monocyte chemoattractant protein-1

rs4128725

1

156219032

3.7*10 -12

3.3*10-8

OR10J1

 

C-reactive protein average exams 2,6,7

rs2794520

1

156491889

2.8*10 -8

4.3*10-5

CRP

 

C-reactive protein average exams 2,6,7

rs2808629

1

156489869

3.2*10 -8

4.8*10-5

CRP

 

C-reactive protein exam 6

rs2794520

1

156491889

1.3*10 -7

3.9*10-4

CRP

 

C-reactive protein exam 6

rs2808629

1

156489869

1.4*10 -7

4.3*10-4

CRP

 

Tumor necrosis factor alpha

rs7552393

1

83966572

5.1*10 -7

0.63

  

C-reactive protein exam 6

rs746961

19

35791730

7.5*10 -7

0.03

ZNF536

 

Bilirubin

rs17532515

4

141745043

1.0*10 -6

9.2*10-6

CLGN, ELMOD2

 

Alanine aminotransferase

rs1998303

9

82644535

1.1*10 -6

0.005

  

Monocyte chemoattractant protein-1

rs10489849

1

156009838

1.1*10 -6

0.10

IGSF4B

 

Alkaline phosphatase

rs10518765

15

52467924

1.1*10 -6

1.7*10-4

  

Vitamin K plasma phylloquinone

rs2387326

10

129823446

1.1*10 -6

0.02

PTPRE, MKI67

 

C-reactive protein average exams 2,6,7

rs1119582

5

125270919

1.2*10 -6

4.2*10-4

  

Vitamin D plasma 25(OH)-D

rs10485165

6

89169536

1.4*10 -6

0.003

  

Atrial natriuretic peptide exam 6

rs1417352

6

107005919

1.8*10 -6

0.009

  

C-reactive protein exam 2

rs583012

10

54964880

1.9*10 -6

0.09

  

Atrial natriuretic peptide exam 6

rs1486139

7

46048968

2.0*10 -6

0.04

  

Atrial natriuretic peptide exam 6

rs1486140

7

46048877

2.2*10 -6

0.06

  

Alanine aminotransferase exam 2

rs10492681

13

39705483

2.2*10 -6

9.9*10-5

  

Vitamin D plasma 25(OH)-D

rs10507577

13

52866092

2.6*10 -6

0.004

  

Atrial natriuretic peptide exam 6

rs1079596

11

112801829

2.6*10 -6

0.03

DRD2

 

Monocyte chemoattractant protein-1

rs1474747

1

155961586

2.8*10 -6

8.7*10-4

IGSF4B

 

CD40 Ligand serum

rs7778619

7

9923216

3.0*10 -6

0.19

  

CD40 Ligand serum

rs8005745

14

76473583

3.5*10 -6

0.01

  

2b. Top 25 associations with biomarkers based on the lowest p value of the FBAT test

Trait

SNP rs ID*

Chr

Physical location (bp)

GEE P-value

FBAT P-value

IN/NEAR gene

 

Monocyte chemoattractant protein-1

rs4128725

1

156219032

3.7*10-12

3.3*10 -8

OR10J1

 

Monocyte chemoattractant protein-1

rs2494250

1

156091324

1.0*10-14

3.5*10 -8

FCER1A, OR10J3

 

B-type natriuretic peptide

rs437021

1

61450291

1.5*10-4

1.0*10 -6

NFIA

 

Vitamin K % undercarboxylated osteocalcin

rs2052028

7

15789103

5.2*10-6

1.1*10 -6

  

CD40 Ligand plasma

rs2372184

3

65673194

0.003

2.5*10 -6

MAGI1

 

Urinary isoprostanes/creatinine

rs717145

20

15826091

0.003

5.0*10 -6

C20orf133

 

CD40 Ligand serum

rs4664604

2

153398916

0.01

8.4*10 -6

ARL6IP6

 

CD40 Ligand serum

rs9288125

2

153348619

0.01

9.1*10 -6

FMNL2, ARL6IP6

 

C-reactive protein exam 7

rs1363258

5

103297593

0.02

9.2*10 -6

  

Bilirubin

rs17532515

4

141745043

1.0*10-6

9.2*10 -6

CLGN, ELMOD2

 

Osteoprotegerin

rs496269

6

79457094

0.03

9.4*10 -6

  

C-reactive protein average 2,6,7

rs1363258

5

103297593

0.009

1.3*10 -5

  

CD40 Ligand serum

rs303939

13

71269472

0.008

1.3*10 -5

DACH1

 

Myeloperoxidase

rs10501981

11

100880825

1.1*10-5

1.4*10 -5

TRPC6

 

Urinary isoprostanes/creatinine

rs1461549

14

24782140

0.26

1.5*10 -5

  

Tumor necrosis factor alpha

rs2353803

7

11060282

0.03

1.5*10 -5

  

Intercellular adhesion molecule-1

rs3849944

9

27550594

5.3*10-6

1.5*10 -5

C9orf72

 

CD40 Ligand serum

rs1986743

2

153412407

0.01

1.6*10 -5

ARL6IP6

 

Gamma-glutamyl transferase

rs962976

12

67006894

0.002

1.6*10 -5

MDM1

 

C-reactive protein average 2,6,7

rs2421608

2

117013763

0.02

1.8*10 -5

  

C-reactive protein exam 2

rs642245

11

86067184

0.03

1.9*10 -5

ME3

 

Tumor necrosis factor receptor-2

rs248328

5

179309691

0.59

1.9*10 -5

TBC1D9B, RNF130

 

C-reactive protein exam 7

rs2390582

1

90655928

0.07

2.0*10 -5

  

Osteoprotegerin

rs9352609

6

79442188

0.04

2.0*10 -5

  

Intercellular adhesion molecule-1

rs744511

14

39166736

3.2*10-4

2.1*10 -5

  

2c. Magnitude and Location of Peak LOD scores > 2.5 for regions in the Biomarker Phenotype Group

Trait

Exam

Chr

Physical location (bp)

Maximum LOD

LOD-1.5 Interval

LOD+1.5 Interval

Maximum LOD WIN*

Monocyte chemoattractant protein-1

7

1

159093573

4.96

154908901

159751221

4.38

Monocyte chemoattractant protein-1

7

10

129553148

4.03

128294406

130084334

3.23

C-reactive protein

5

1

154745847

3.53

153213133

156567571

3.28

Monocyte chemoattractant protein-1

7

17

13630703

3.33

10874193

16776778

2.54

Intercellular adhesion molecule-1

7

1

203535232

2.95

202207846

215367881

2.93

Monocyte chemoattractant protein-1

7

7

92544810

2.94

88727093

105546050

2.01

Tumor necrosis factor receptor 2

7

1

54001041

2.92

43070922

60590679

2.95

Gamma-glutamyl transferase

2

3

26424584

2.89

24621158

27418642

2.96

B-type natriuretic peptide

6

12

4140574

2.77

132045

8137669

No outliers

Gamma-glutamyl transferase

2

10

129553148

2.67

120112006

132560638

2.79

Vitamin D plasma 25(OH)-D

6/7

8

140624328

2.67

138952328

146039126

2.68

B-type natriuretic peptide

6

19

34016706

2.59

13425865

43186344

No outliers

Myeloperoxidase

7

19

11295505

2.56

3026853

16489850

2.56

Alkaline phosphatase

2

6

170538204

WIN

162441307

170788550

2.55

Osteoprotegerin

7

13

75274475

2.52

71928655

81228082

2.95

bp = base pair; Chr = chromosome; WIN = Winsorized.

dbSNP positions are from NCBI Build 35 (hg17);

LD between rs2494250 and rs4128725 (top MCP1 SNPs): D' = 0.724 and r squared = 0.196.

LD between rs2794520 and rs2808629 (top CRP SNPs): D' = 1.0 and r squared = 1.0.

*Winsorized LOD scores were run for this manuscript, and are not displayed on the web.

We estimated the amount of variability in biomarker concentrations explained by the 4 most statistically significant SNPs in the GEE model using a pseudo measure of R2 based on log-likelihood estimates [36]. The two most statistically significant GEE SNPs explained about 7% and 4% of the variability in MCP1 concentrations (R2 = 0.070 for rs2494250 and R2 = 0.043 for rs4128725); for CRP concentrations averaged over examinations 2, 6, and 7 the two most statistically significant GEE SNPs explained 2.3% of the variability [R2 = 0.023 for rs2794520 and rs2808629) [36]. We also examined the linkage disequilibrium between the most statistically significant GEE SNPs: rs2494250 and rs4128725 had a D' = 0.724 and an r2 = 0.196, whereas rs2794520 and rs2808629 served as perfect proxies for each other (D' = 1; r2 = 1).

With FBAT, 11 SNPs were associated with biomarker concentrations with a p < 10-6. The two most statistically significant SNPs for FBAT were the same two SNPs observed with GEE: MCP1 concentrations were significantly associated with rs4128725, p = 3.28*10-8, and rs2494250, p = 3.55*10-8 (Table 2b). In addition, B-type natriuretic peptide (rs437021, p = 1.01*10-6) and Vitamin K% undercarboxylated osteocalcin (rs2052028, p = 1.07*10-6) also were nominally statistically significantly associated.

In Table 2c we list the magnitude and location of LOD scores > 2.5 observed for the circulating biomarker traits. Because we were concerned that some of the LOD scores might be inflated by individuals with extreme marker concentrations, we reanalyzed the LOD scores on Winsorized residuals. The peak Winsorized LOD scores observed were for the biomarkers MCP1 (4.38, chromosome 1), and CRP (3.23, chromosome 10; 3.28, chromosome 1). Of note the 1.5 LOD support intervals for the linkage peaks on chromosome 1 included the SNPs significantly associated with MCP1 and CRP reported above (GEE model).

In an effort to potentially uncover genetic pleiotropy we display in Table 3 two ways to synthesize findings across phenotypes. We examined 3 correlated inflammatory biomarker phenotypes, interleukin-6, CRP and fibrinogen, and report SNPs that were significantly associated with all 3 phenotypes by GEE or FBAT at p < 0.01 (Table 3a). We also examined phenotypes within a specific biomarker category including CRP over multiple examinations, liver function tests and vitamin concentrations (nutrients involved in bone health [37, 38]), and display in Table 3b SNPs significant by either FBAT or GEE at a p < 0.01 for all of the phenotypes in a given phenotype cluster.
Table 3

Combined phenotypes

Trait

SNP rs ID

Chr

Physical location (bp)

GEE P-value

FBAT P-value

IN/NEAR gene

3a. SNPs significant for 3 correlated phenotypes at exam 7 by either GEE or FBAT at p < 0.01

Interleukin-6, C-reactive protein and Fibrinogen

rs10511884

9

31668988

5.7*10-5

0.0065

 
 

rs1887027

10

6153788

2.6*10-4

0.19

IL2RA, RBM17

 

rs2831617

21

28481515

6.2*10-4

0.0027

 
 

rs2831620

21

28481869

6.4*10-4

0.0022

 
 

rs2831618

21

28481749

6.4*10-4

0.0020

 
 

rs2044401

9

31659518

6.6*10-4

0.12

 
 

rs1457590

3

21530978

0.0019

0.16

ZNF659

 

rs6848323

4

113286305

0.0022

0.14

 
 

rs3110134

8

60260538

0.0025

0.12

 
 

rs2016740

4

113238018

0.0039

0.17

 
 

rs719006

15

59210481

0.0044

0.76

RORA

 

rs877936

4

113238472

0.0055

0.31

 
 

rs1436136

4

113421130

0.0062

0.039

 
 

rs1436336

3

106156256

0.0067

0.0040

 
 

rs698270

3

137592210

0.0086

0.020

STAG1

 

rs847428

7

16803192

0.019

0.025

 
 

rs2359763

3

23424931

0.024

0.0025

 
 

rs7969455

12

7757402

0.059

0.0015

DPPA3

 

rs10503717

8

22634817

0.06

0.0028

 
 

rs4899940

14

87623621

0.11

0.0019

 

3b. Combined phenotypes within a specific biological domain

C-reactive protein: exams 2, 5, 6, 7

rs2808629

1

156489869

6.9*10-5

4.7*10-4

NFIA, CRP

 

rs2794520

1

156491889

6.1*10-5

4.85*10-4

FCER1A, CRP

 

rs6563212

13

35380415

7.3*10-4

0.30

DCAMKL1

 

rs11626844

14

72413330

5.1*10-3

0.17

OR10J1, DPF3

 

rs9319160

13

84918646

0.002

0.09

 
 

rs910232

1

17143820

0.002

0.01

MAGI1, PADI2

Liver function: Alkaline phosphatase; AST; ALT; GGT

rs4911146

20

32103708

0.01

8.4*10-6

ARL6IP6, RALY

 

rs953402

3

5986639

0.01

9.1*10-6

FMNL2

Vitamin D, Vitamin K phylloquinone & Vitamin K % undercarboxylated osteocalcin

rs1376544

4

180293700

0.02

9.2*10-6

 

Chr = chromosome;

For a given SNP, all of the phenotypes either FBAT or GEE significant if FBAT < 0.01 for particular SNP;

P-values = the geometric mean of the p-value for all traits within the biomarker cluster

In Table 4 we compared our data with previously reported phenotype-genotype associations in the published literature on systemic biomarker concentrations: bilirubin concentrations (TA repeat in UGT1A1) [39, 40]; CRP (CRP) [20, 32, 4150], intercellular adhesion molecule-1 (ICAM1) [5154], interleukin-6 (IL6) [5562], and MCP1 (CCL2 = MCP1 gene [63, 64]). Unfortunately, there were no SNPs within 60 KB of the ICAM1 gene on the Affymetrix 100K chip. There was no association between bilirubin concentrations and 1 SNP within 30 kb (rs741159) + 2 more SNPs within 50 kb (rs726017 and rs6752792) of a previously reported TA repeat in UGT1A1. Additionally, there was no association between interleukin-6 concentrations and SNPs in the IL6 region despite one SNP in high LD (linkage disequilibrium; r2 = 0.819) with the previously reported rs1800795 (-174G/C) SNP. Similarly, we did not observe an association between MCP1 concentrations and SNPs in the CCL2 region, despite one SNP with a high r2 (0.956) with the SNP previously reported in the literature. For CRP concentrations, we had 2 SNPs in perfect LD with rs1205, and we observed strong evidence for replication. However, it should be noted that this association has been previously reported by Framingham investigators in unrelated participants [32]. Similarly, rs431568, which is in high LD (r2 = 0.83) with 2 previously associated SNPs (rs3116653 and rs1417938), was highly associated with many of the CRP phenotypes.
Table 4

Comparison with the prior literature

Gene

rs number previous reports

# Affy SNPs within 60 kb

rs ID Affy SNPs

Chr

D'

r2

Distance Associated SNP

MAF

FBAT p-value

GEE p-value

IL6

rs1800795

= -174G/C

7

rs6461667

7

1

0.82

30098

0.36

0.09

0.66

MCP1

rs1024611

13

rs10491109

17

1

0.04

30762

0.15

0.048

0.13

   

rs1080327

 

1

0.96

11878

0.25

0.78

0.35

   

rs1860181

 

0.92

0.27

37799

0.45

0.04

0.11

   

rs1860182

 

0.92

0.27

37649

0.45

0.046

0.11

   

rs3815341

 

1

0.02

34637

0.05

0.001

0.50

CRP average 2,6,7

rs1205

37

rs1446959

1

0.56

0.12

75429

0.39

0.86

0.002

   

rs1891187

 

0.39

0.05

53180

0.33

0.30

0.02

   

rs2808629

 

1

1

5437

0.34

4.8*105

3.2*10-8

   

rs2794520

 

1

1

3417

0.34

4.3*10-5

2.8*10-8

   

rs4131568

 

0.63

0.12

39823

0.30

0.004

0.001

 

rs1417938

 

rs1446959

 

0.5

0.16

77382

0.39

0.86

0.002

   

rs1891187

 

0.29

0.07

55133

0.33

0.30

0.02

   

rs2808629

 

1

0.25

7390

0.34

4.8*10-5

3.2*10-8

   

rs2794520

 

1

0.25

5370

0.34

4.3*10-5

2.8*10-8

   

rs4131568

 

1

0.83

37870

0.30

0.004

0.001

   

rs1446959

 

0.66

0.03

72832

0.39

0.86

0.002

 

rs3093077

 

rs1891187

 

0.47

0.02

50583

0.33

0.30

0.02

   

rs2808629

 

1

0.03

2840

0.34

4.8*10-5

3.2*10-8

   

rs2794520

 

1

0.03

820

0.34

4.3*10-5

2.8*10-8

   

rs4131568

 

1

0.03

42420

0.30

0.004

0.001

   

rs1446959

 

0.51

0.17

90106

0.39

0.86

0.002

 

rs3116653

 

rs1891187

 

0.31

0.08

67857

0.33

0.30

0.02

   

rs2808629

 

1

0.25

20114

0.34

4.8*10-5

3.2*10-8

   

rs2794520

 

1

0.25

18094

0.34

4.3*10-5

2.8*10-8

   

rs4131568

 

1

0.83

25146

0.30

0.004

0.001

Displayed are SNPs that are either in the highest LD (r2) with previously reported SNPs or that have an FBAT or GEE p-value < 0.05.

For bilirubin concentrations in Framingham study unrelated participants we previously reported significant linkage to chromosome 2q telomere [39] and a significant association to a TA repeat UGT1A1, there were no association between bilirubin concentrations and 1 SNP within 30 kb (rs741159) + 2 more SNPs within 50 kb (rs726017 and rs6752792). The previously reported UGT1A1 variant is not a SNP and therefore not in HapMap; we have no LD information and cannot assess whether the association previous reported is also present in the current sample. ICAM1on chromosome 19 has 3 reported SNPs in literature (rs1799969, rs5491, rs5498), but there were no Affymetrix SNPs within 60 KB of the gene.

CCL2[Other associated SNPs: rs2857654, rs1024610, rs2857657 are NOT in HapMap, so no LD information was available.

CRP2 SNPs are in perfect LD with rs1205. The previously reported triallelic SNP rs3091244 is not in HapMap. CRP association was previously reported in Framingham unrelated participants [32].

Discussion

In collaboration with NCBI we have web-posted our unfiltered biomarker-genotype associations and linkage results to provide a resource to investigators seeking to understand and replicate their biomarker-genotype associations. We submit that the findings of highest priority for follow-up are associations that were detected by several statistical approaches. MCP1 was associated with 2 SNPs on chromosome 1 (rs4128725 and rs2494250) with p-values in the 10-8 by FBAT, ≤ 10-12 by GEE. Acknowledging that linkage is less powerful and accurate, we note that the 1.5 support interval for the MCP1 linkage peak (Winsorized maximum LOD 4.38) on chromosome 1 supports the GEE and FBAT analyses. Findings for CRP (chromosome 1), brain natriuretic peptide (chromosome 1) and Vitamin K % undercarboxylated osteocalcin (Chromosome 7) are also of potential priority for follow-up. We acknowledge that the ultimate validation of our findings will require replication in other cohorts and functional studies.

A fundamental challenge of GWAS tests is sorting through associations and prioritizing SNPs for follow-up. In the absence of external replication, one approach to synthesizing findings is to examine associations across similar biological domains, which may capture pleiotropy. We presented the exploratory analyses in Tables 3a and 3b, but reiterate that the findings will need to be examined in other cohorts.

Do the findings represent true positive genetic associations?

It is notable that some of the associations with the strongest statistical support were for associations between a gene and its protein product (e.g. CRP gene and CRP concentration). Cis-acting regulatory variants have been shown to influence mRNA and protein levels for many genes [65]. Studies involving additional biomarker phenotypes and variants (e.g. Affymetrix 500 K Chip) should clarify whether cis- or trans-acting regulatory variants explain the greatest proportion of phenotypic variation.

With GWAS, which typically test for the association of 1000s of SNPs with multiple traits, it is difficult for any specific association to achieve genome wide significance. For instance, a strict Bonferroni correction for the 30 traits tested in the present study with both age/sex- and multivariable-adjusted models and 2 statistical methods (0.05/(70,987*30*2*2) would require a p = 5.9 × 10-9. We submit that the most significant association in the selected biomarker group, the FCER1A rs2494250 SNP with MCP1 concentrations achieved genome-wide significance with a GEE p = 1.0*10-14 and a FBAT p = 3.5*10-8. It should be noted that rs2494250 and rs4128725 are in modest linkage disequilibrium (D' = 0.724 and r squared = 0.196) and hence, may be serving as proxies for the same causal SNP.

Several human and experimental studies suggest that the association between FCER1A and MCP1 concentrations is biologically plausible. FCER1A codes for the high affinity Fc receptor fragment for IgE. In vitro experiments with rat mast cells demonstrated that if aggregated the high affinity receptor for IgE (FcεRI) increased gene transcription and secretion of MCP1 [66]. Similarly, in mice mast cells if the FcεRI was occupied by small amounts IgE/antigen, MCP1 mRNA increased significantly [67]. In humans IgE and MCP1 concentrations are both increased in occupational asthma [68, 69]. Similar to the animal data, human mast cells exposed to anti-IgE antibody or to IgE released MCP1 [7072].

Comparison with prior literature

Our efforts to compare our findings with associations previously reported in the literature underscore some of the challenges in genetic association studies. The ICAM1 gene did not have any markers within 60 kb on the Affymetrix 100K chip. Of the 4 genes that did have SNPs in the marker genomic region coding, only the CRP association was replicated in our cohort; however as noted above we [32], as well as others [20], have previously reported this association. For bilirubin concentrations we previously reported significant linkage to chromosome 2q telomere [39] and a significant association to a TA repeat in UGT1A1, under this linkage peak [40] in Framingham unrelated participants. However, there was no association between bilirubin concentrations and the 3 SNP within 60 kb of UGT1A1. The previously reported interleukin-6-IL6 and the MCP1-CCL2 associations were not replicated. Of note, our group previously reported that rs1024611 [in CCL2] was associated with MCP1 concentrations in unrelated participants [63]; the association was nowhere close to significant in the present report (FBAT p = 0.78; GEE p = 0.35) Possible explanations of the failure to confirm the previously reported Framingham study MCP1-CCL2 association may stem from the current report having a smaller sample size (n = 989), using different genetic markers, and being conducted with an additive genetic model in related participants, as opposed to the prior study using unrelated participants (n = 1602) with recessive and dominant models. In a recent meta-analysis of phenotype-genotype association studies, only about one third (8 of 25) of the associations examined were replicated [73]. There are many plausible explanations why we did not replicate previously reported phenotype-genotype associations. Previous reports could represent false positive findings, or the present and prior study cohorts may differ on key factors, which may modify the phenotype-genotype associations, or our lack of replication may represent a false negative report because of inadequate statistical power [73, 74].

Strengths and limitations

The strengths of the present study include a comprehensively characterized community-based cohort, with biomarker phenotypes routinely assessed with careful attention to quality control. However, the cohort was largely middle-aged to elderly, and white of European descent, so the findings may not be generalizable to individuals who are younger or of other ethnicity/racial descent. DNA was collected at the 5th and 6th examinations, which may have introduced a survival bias. In addition, our study was susceptible to false negative findings because of the moderate size of the cohort; we lacked power to detect modest associations. Conversely, similar to most GWAS, the reported associations and linkage may represent false positive findings from multiple statistical testing.

Conclusions and future directions

The Framingham GWAS and the web posting of the unfiltered results represent a unique resource to discover potentially novel genetic influences on systemic biomarker variability. We acknowledge that the newly described associations will need to be replicated in other studies.

Abbreviations

bp: 

base pair

Chr: 

chromosome

CRP: 

C-reactive protein

FBAT: 

Family Based Association Tests

GEE: 

Generalized Estimating Equations

GWAS: 

Genome-wide association studies

LD: 

linkage disequilibrium

LOD: 

logarithm of the odds (base 10)

MCP-1: 

monocyte chemoattractant protein-1

SNPs: 

single nucleotide polymorphisms.

Declarations

Acknowledgements

The investigators would like to express their gratitude to the Framingham Heart Study participants and key collaborators: Fox CS, Jacques PF, Lee DS, Lipinska I, Massaro JM, Murabito JM, O'Donnell CJ, Seshadri S, Yang Q. The core examinations were funded by N01-HC25195. A portion of the research was conducted using the Boston University Linux Cluster for Genetic Analysis (LinGA) funded by the NIH NCRR (National Center for Research Resources) Shared Instrumentation grant (1S10RR163736-01A1). Inflammatory markers were measured via HL064753, HL076784, AG028321 (EJB), HL71039 (RSV) and 2 K24HL04334 (RSV); osteoprotegerin work was supported by HL064753, HL076784, AG028321 (EJB) and the Doris Duke Charitable Foundation and NIH 1K23 HL083102 (SK). TNF-alpha concentrations were measured via American Diabetes Association Career Development Award and NCRR GCRC M01-RR-01066 (JBM); Natriuretic peptides were measured by Shionogi & Co., Ltd. with an unrestricted research grant; Liver function tests were funded by the core contract; Vitamins were measured by federal funds from the U.S. Department of Agriculture, Agricultural Research Service under Cooperative Agreement No. 58-1950-001 and No. 58-1950-4-401, National Institute of Aging (AG14759).

This article has been published as part of BMC Medical Genetics Volume 8 Supplement 1, 2007: The Framingham Heart Study 100,000 single nucleotide polymorphisms resource. The full contents of the supplement are available online at http://www.biomedcentral.com/1471-2350/8?issue=S1.

Authors’ Affiliations

(1)
The National Heart Lung and Blood Institute's Framingham Heart Study
(2)
School of Medicine, Boston University
(3)
Whitaker Cardiovascular Institute, Boston University
(4)
School of Public Health, Boston University
(5)
Department of Mathematics and Statistics
(6)
Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University
(7)
Broad Institute of Massachusetts Institute of Technology
(8)
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Harvard University
(9)
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Harvard University
(10)
Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health
(11)
Emory School of Medicine

References

  1. Vasan RS: Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006, 113: 2335-2362. 10.1161/CIRCULATIONAHA.104.482570.View ArticlePubMedGoogle Scholar
  2. Nabel EG: Genomic medicine and cardiovascular disease. Simon Dack Lecture. The American College of Cardiology. 3-11-2006., [http://www.nhlbi.nih.gov/directorspage/pageimages/03-11-06-acc_dack_nabel.pdf]
  3. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Munzel T, Yusuf S: Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006, 114: 201-208. 10.1161/CIRCULATIONAHA.105.590927.View ArticlePubMedGoogle Scholar
  4. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005, 293: 1609-1616. 10.1001/jama.293.13.1609.View ArticlePubMedGoogle Scholar
  5. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004, 350: 655-663. 10.1056/NEJMoa031994.View ArticlePubMedGoogle Scholar
  6. Wannamethee G, Ebrahim S, Shaper AG: Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol. 1995, 142: 699-708.PubMedGoogle Scholar
  7. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, Wang TJ, Benjamin EJ, D'Agostino RB, Vasan RS: Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007, 27: 127-133. 10.1161/01.ATV.0000251993.20372.40.View ArticlePubMedGoogle Scholar
  8. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R: Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol. 1990, 19: 559-563. 10.1093/ije/19.3.559.View ArticlePubMedGoogle Scholar
  9. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000, 342: 836-843. 10.1056/NEJM200003233421202.View ArticlePubMedGoogle Scholar
  10. Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998, 279: 1477-1482. 10.1001/jama.279.18.1477.View ArticlePubMedGoogle Scholar
  11. Kuller LH, Tracy RP, Shaten J, Meilahn EN, the MRFIT Research Group: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996, 144: 537-547.View ArticlePubMedGoogle Scholar
  12. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J: Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998, 351: 88-92. 10.1016/S0140-6736(97)09032-6.View ArticlePubMedGoogle Scholar
  13. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999, 106: 506-512. 10.1016/S0002-9343(99)00066-2.View ArticlePubMedGoogle Scholar
  14. Dupuis J, Larson MG, Vasan RS, Massaro JM, Wilson PW, Lipinska I, Corey D, Vita JA, Keaney JF, Benjamin EJ: Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: evidence for susceptibility loci on 1q. Atherosclerosis. 2005, 182: 307-314. 10.1016/j.atherosclerosis.2005.02.015.View ArticlePubMedGoogle Scholar
  15. Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, Tracy RP: Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis. 2001, 154: 681-689. 10.1016/S0021-9150(00)00586-4.View ArticlePubMedGoogle Scholar
  16. Wang TJ, Larson MG, Levy D, Benjamin EJ, Corey D, Leip EP, Vasan RS: Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation. 2003, 108: 13-16. 10.1161/01.CIR.0000081657.83724.A7.View ArticlePubMedGoogle Scholar
  17. Bathum L, Petersen HC, Rosholm JU, Hyltoft PP, Vaupel J, Christensen K: Evidence for a substantial genetic influence on biochemical liver function tests: results from a population-based Danish twin study. Clin Chem. 2001, 47: 81-87.PubMedGoogle Scholar
  18. Pilia G, Chen WM, Scuteri A, Orru M, Albai G, Dei M, Lai S, Usala G, Lai M, Loi P, Mameli C, Vacca L, Deiana M, Olla N, Masala M, Cao A, Najjar SS, Terracciano A, Nedorezov T, Sharov A, Zonderman AB, Abecasis GR, Costa P, Lakatta E, Schlessinger D: Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet. 2006, 2: e132-10.1371/journal.pgen.0020132.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Hunter D, De Lange M, Snieder H, MacGregor AJ, Swaminathan R, Thakker RV, Spector TD: Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res. 2001, 16: 371-378. 10.1359/jbmr.2001.16.2.371.View ArticlePubMedGoogle Scholar
  20. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, Liu K, Williams OD, Iribarren C, Lewis EC, Fornage M, Boerwinkle E, Gross M, Jaquish C, Nickerson DA, Myers RM, Siscovick DS, Reiner AP: Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet. 2005, 77: 64-77. 10.1086/431366.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Cupples LA, Arruda HT, Benjamin EJ, D'Agostino RB, Demissie S, DeStefano AL, Dupuis J, Falls K, Fox CS, Gottlieb DJ, Govindaraju DR, Guo CY, Heard-Costa NL, Hwang SJ, Kathiresan S, Kiel DP, Laramie JM, Larson MG, Levy D, Liu CY, Lunetta KL, Mailman MD, Manning AK, Meigs JB, Murabito JM, Newton-Cheh C, O'Connor GT, O'Donnell CJ, Pandey MA, Seshadri S, Vasan RS, Wang ZY, Wilk JB, Wolf PA, Yang Q, Atwood LD: The Framingham Heart Study 100K SNP genome-wide association study resource: Overview of 17 phenotype working group reports. BMC Med Genet. 2007, 8 (Suppl 1): S1-PubMed CentralView ArticlePubMedGoogle Scholar
  22. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP: An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979, 110: 281-290.PubMedGoogle Scholar
  23. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D: Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002, 288: 1252-1259. 10.1001/jama.288.10.1252.View ArticlePubMedGoogle Scholar
  24. Walters MI, Gerarde HW: A microspectrophotometric method for the determination of bilirubin. Microchemical J. 1968, 13: 253-272. 10.1016/0026-265X(68)90015-5.View ArticleGoogle Scholar
  25. Djousse L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC: Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol. 2001, 87: 1196-1200. 10.1016/S0002-9149(01)01494-1.View ArticlePubMedGoogle Scholar
  26. Roy AV: Rapid method for determining alkaline phosphatase activity in serum with thymolphthalein monophosphate. Clin Chem. 1970, 16: 431-436.PubMedGoogle Scholar
  27. Proksch GJ, Bonderman DP, Griep JA: AutoAnalyzer assay for serum alkaline phosphatase activity, with sodium thymolphthalein monophosphate as substrate. Clin Chem. 1973, 19: 103-105.PubMedGoogle Scholar
  28. Henry RJ, Chiamori N, Golub OJ, Berkman S: Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase. Am J Clin Pathol. 1960, 34: 381-398.PubMedGoogle Scholar
  29. Davidson KW, Sadowski JA: Determination of vitamin K compounds in plasma or serum by high-performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection. Methods Enzymol. 1997, 282: 408-421.View ArticlePubMedGoogle Scholar
  30. Gundberg CM, Hauschka PV, Lian JB, Gallop PM: Osteocalcin: isolation, characterization, and detection. Methods Enzymol. 1984, 107: 516-544.View ArticlePubMedGoogle Scholar
  31. Gundberg CM, Nieman SD, Abrams S, Rosen H: Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. J Clin Endocrinol Metab. 1998, 83: 3258-3266. 10.1210/jc.83.9.3258.PubMedGoogle Scholar
  32. Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, Keaney JF, Wilson PW, Newton-Cheh C, Musone SL, Camargo AL, Drake JA, Levy D, O'Donnell CJ, Hirschhorn JN, Benjamin EJ: Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation. 2006, 113: 1415-1423. 10.1161/CIRCULATIONAHA.105.591271.View ArticlePubMedGoogle Scholar
  33. Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, Illig T, Wichmann HE, Meitinger T, Hunter D, Hu FB, Colditz G, Hinney A, Hebebrand J, Koberwitz K, Zhu X, Cooper R, Ardlie K, Lyon H, Hirschhorn JN, Laird NM, Lenburg ME, Lange C, Christman MF: A common genetic variant is associated with adult and childhood obesity. Science. 2006, 312: 279-283. 10.1126/science.1124779.View ArticlePubMedGoogle Scholar
  34. Abecasis GR, Cherny SS, Cookson WO, Cardon LR: Merlin – rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet. 2002, 30: 97-101. 10.1038/ng786.View ArticlePubMedGoogle Scholar
  35. Almasy L, Blangero J: Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998, 62: 1198-1211. 10.1086/301844.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Nagelkerke NJD: A note on a general definition of the coefficient of determination. Biometrika. 1991, 78: 691-692. 10.1093/biomet/78.3.691.View ArticleGoogle Scholar
  37. Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ: Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2006, 166: 1256-1261. 10.1001/archinte.166.12.1256.View ArticlePubMedGoogle Scholar
  38. Szulc P, Chapuy MC, Meunier PJ, Delmas PD: Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest. 1993, 91: 1769-1774.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Lin JP, Cupples LA, Wilson PW, Heard-Costa N, O'Donnell CJ: Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study. Am J Hum Genet. 2003, 72: 1029-1034. 10.1086/373964.PubMed CentralView ArticlePubMedGoogle Scholar
  40. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, Kronenberg F: Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006, 114: 1476-1481. 10.1161/CIRCULATIONAHA.106.633206.View ArticlePubMedGoogle Scholar
  41. Zee RY, Ridker PM: Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis. 2002, 162: 217-219. 10.1016/S0021-9150(01)00703-1.View ArticlePubMedGoogle Scholar
  42. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP: Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun. 2002, 3: 14-19. 10.1038/sj.gene.6363820.View ArticlePubMedGoogle Scholar
  43. Suk HJ, Ridker PM, Cook NR, Zee RY: Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis. 2005, 178: 139-145. 10.1016/j.atherosclerosis.2004.07.033.View ArticlePubMedGoogle Scholar
  44. Davey SG, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, Day IN, Ebrahim S: Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol. 2005, 25: 1051-1056. 10.1161/01.ATV.0000160351.95181.d0.View ArticleGoogle Scholar
  45. Balistreri CR, Vasto S, Listi F, Grimaldi MP, Lio D, Colonna-Romano G, Caruso M, Caimi G, Hoffmann E, Caruso C, Candore G: Association between +1059G/C CRP polymorphism and acute myocardial infarction in a cohort of patients from Sicily: a pilot study. Ann N Y Acad Sci. 2006, 1067: 276-281. 10.1196/annals.1354.036.View ArticlePubMedGoogle Scholar
  46. Miller DT, Zee RY, Suk DJ, Kozlowski P, Chasman DI, Lazarus R, Cook NR, Ridker PM, Kwiatkowski DJ: Association of Common CRP Gene Variants with CRP Levels and Cardiovascular Events. Ann Hum Genet. 2005, 69: 623-638. 10.1111/j.1529-8817.2005.00210.x.View ArticlePubMedGoogle Scholar
  47. Eklund C, Lehtimaki T, Hurme M: Epistatic effect of C-reactive protein (CRP) single nucleotide polymorphism (SNP) +1059 and interleukin-1B SNP +3954 on CRP concentration in healthy male blood donors. Int J Immunogenet. 2005, 32: 229-232.View ArticlePubMedGoogle Scholar
  48. Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld CD, Williams A, Zakharkin SO, George V, Allison DB, Cooper GS, Xie F, Fan Z, Edberg JC, Kimberly RP: Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med. 2005, 83: 440-447. 10.1007/s00109-005-0658-0.View ArticlePubMedGoogle Scholar
  49. D'Aiuto F, Casas JP, Shah T, Humphries SE, Hingorani AD, Tonetti MS: C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis. 2005, 179: 413-417. 10.1016/j.atherosclerosis.2004.10.036.View ArticlePubMedGoogle Scholar
  50. Kovacs A, Green F, Hansson LO, Lundman P, Samnegard A, Boquist S, Ericsson CG, Watkins H, Hamsten A, Tornvall P: A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis. 2005, 178: 193-198. 10.1016/j.atherosclerosis.2004.08.018.View ArticlePubMedGoogle Scholar
  51. Register TC, Burdon KP, Lenchik L, Bowden DW, Hawkins GA, Nicklas BJ, Lohman K, Hsu FC, Langefeld CD, Carr JJ: Variability of serum soluble intercellular adhesion molecule-1 measurements attributable to a common polymorphism. Clin Chem. 2004, 50: 2185-2187. 10.1373/clinchem.2004.036806.View ArticlePubMedGoogle Scholar
  52. Puthothu B, Krueger M, Bernhardt M, Heinzmann A: ICAM1 amino-acid variant K469E is associated with paediatric bronchial asthma and elevated sICAM1 levels. Genes Immun. 2006, 7: 322-326. 10.1038/sj.gene.6364302.View ArticlePubMedGoogle Scholar
  53. Kronig H, Riedel M, Schwarz MJ, Strassnig M, Moller HJ, Ackenheil M, Muller N: ICAM G241A polymorphism and soluble ICAM-1 serum levels: evidence for an active immune process in schizophrenia. Neuroimmunomodulation. 2005, 12: 54-59. 10.1159/000082364.View ArticlePubMedGoogle Scholar
  54. Ponthieux A, Lambert D, Herbeth B, Droesch S, Pfister M, Visvikis S: Association between Gly241Arg ICAM-1 gene polymorphism and serum sICAM-1 concentration in the Stanislas cohort. Eur J Hum Genet. 2003, 11: 679-686. 10.1038/sj.ejhg.5201033.View ArticlePubMedGoogle Scholar
  55. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, Humphries SE: Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol. 2001, 21: 1458-1463.View ArticlePubMedGoogle Scholar
  56. Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, Macchioni P, Bajocchi G, Catanoso MG, Pulsatelli L, Consonni D, Salvarani C: Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol. 2006, 33: 703-708.PubMedGoogle Scholar
  57. Liu Y, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, Smith MW, Coresh J: IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol. 2006, 17: 863-870. 10.1681/ASN.2005050465.View ArticlePubMedGoogle Scholar
  58. Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, Polesel J, Talamini R, Stivala F, Mazzarino MC, Malaponte G: Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol. 2006, 59: 211-215. 10.1136/jcp.2004.025452.PubMed CentralView ArticlePubMedGoogle Scholar
  59. Ravaglia G, Forti P, Maioli F, Chiappelli M, Dolzani P, Martelli M, Bianchin M, Mariani E, Bolondi L, Licastro F: Associations of the -174 G/C interleukin-6 gene promoter polymorphism with serum interleukin 6 and mortality in the elderly. Biogerontology. 2005, 6: 415-423. 10.1007/s10522-005-4908-x.View ArticlePubMedGoogle Scholar
  60. Cardellini M, Perego L, D'Adamo M, Marini MA, Procopio C, Hribal ML, Andreozzi F, Frontoni S, Giacomelli M, Paganelli M, Pontiroli AE, Lauro R, Folli F, Sesti G: C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care. 2005, 28: 2007-2012. 10.2337/diacare.28.8.2007.View ArticlePubMedGoogle Scholar
  61. Barbieri M, Rizzo MR, Papa M, Acampora R, De Angelis L, Olivieri F, Marchegiani F, Franceschi C, Paolisso G: Role of interaction between variants in the PPARG and interleukin-6 genes on obesity related metabolic risk factors. Exp Gerontol. 2005, 40: 599-604. 10.1016/j.exger.2005.05.004.View ArticlePubMedGoogle Scholar
  62. Haddy N, Sass C, Maumus S, Marie B, Droesch S, Siest G, Lambert D, Visvikis S: Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur J Hum Genet. 2005, 13: 109-117. 10.1038/sj.ejhg.5201294.View ArticlePubMedGoogle Scholar
  63. McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF, Larson MG, Vasan RS, Hirschhorn JN, O'Donnell CJ, Murphy PM, Benjamin EJ: CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation. 2005, 112: 1113-1120. 10.1161/CIRCULATIONAHA.105.543579.View ArticlePubMedGoogle Scholar
  64. Joven J, Coll B, Tous M, Ferre N, Alonso-Villaverde C, Parra S, Camps J: The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattractant protein-1 and carotid atherosclerosis. Clin Chim Acta. 2006, 368: 114-119. 10.1016/j.cca.2005.12.014.View ArticlePubMedGoogle Scholar
  65. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT: Mapping determinants of human gene expression by regional and genome-wide association. Nature. 2005, 437: 1365-1369. 10.1038/nature04244.PubMed CentralView ArticlePubMedGoogle Scholar
  66. Eglite S, Morin JM, Metzger H: Synthesis and secretion of monocyte chemotactic protein-1 stimulated by the high affinity receptor for IgE. J Immunol. 2003, 170: 2680-2687.View ArticlePubMedGoogle Scholar
  67. Gonzalez-Espinosa C, Odom S, Olivera A, Hobson JP, Martinez ME, Oliveira-Dos-Santos A, Barra L, Spiegel S, Penninger JM, Rivera J: Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells. J Exp Med. 2003, 197: 1453-1465. 10.1084/jem.20021806.PubMed CentralView ArticlePubMedGoogle Scholar
  68. Malo JL, L'Archeveque J, Lummus Z, Bernstein D: Changes in specific IgE and IgG and monocyte chemoattractant protein-1 in workers with occupational asthma caused by diisocyanates and removed from exposure. J Allergy Clin Immunol. 2006, 118: 530-533. 10.1016/j.jaci.2006.04.022.View ArticlePubMedGoogle Scholar
  69. Bernstein DI, Cartier A, Cote J, Malo JL, Boulet LP, Wanner M, Milot J, L'Archeveque J, Trudeau C, Lummus Z: Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma. Am J Respir Crit Care Med. 2002, 166: 445-450. 10.1164/rccm.2109018.View ArticlePubMedGoogle Scholar
  70. Baghestanian M, Hofbauer R, Kiener HP, Bankl HC, Wimazal F, Willheim M, Scheiner O, Fureder W, Muller MR, Bevec D, Lechner K, Valent P: The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells. Blood. 1997, 90: 4438-4449.PubMedGoogle Scholar
  71. Matsuda K, Piliponsky AM, Iikura M, Nakae S, Wang EW, Dutta SM, Kawakami T, Tsai M, Galli SJ: Monomeric IgE enhances human mast cell chemokine production: IL-4 augments and dexamethasone suppresses the response. J Allergy Clin Immunol. 2005, 116: 1357-1363. 10.1016/j.jaci.2005.08.042.View ArticlePubMedGoogle Scholar
  72. Gosset P, Tillie-Leblond I, Oudin S, Parmentier O, Wallaert B, Joseph M, Tonnel AB: Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors. J Allergy Clin Immunol. 1999, 103: 289-297. 10.1016/S0091-6749(99)70504-X.View ArticlePubMedGoogle Scholar
  73. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003, 33: 177-182. 10.1038/ng1071.View ArticlePubMedGoogle Scholar
  74. Hegele RA: SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol. 2002, 22: 1058-1061. 10.1161/01.ATV.0000026801.56080.14.View ArticlePubMedGoogle Scholar

Copyright

© Benjamin et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.